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1  | BACKGROUND
Atrial	fibrillation	is	the	most	common	cardiac	arrhythmia,	affecting	
approximately	1.5%	to	2%	of	the	general	population,	increasing	by	
a	further	1.8%	in	the	presence	of	cancer.1	Atrial	fibrillation	becomes	
more	prevalent	with	 age	 and	 increases	 the	overall	 risk	of	 embolic	
stroke	five‐fold.2,3	Anticoagulation	has	long	been	established	as	the	
most	effective	way	to	prevent	embolic	stroke,	but	this	is	challenging	
in	the	cancer	setting	since	it	is	associated	with	a	higher	rate	of	clini‐
cally	relevant	non‐major	and	major	bleeding.4	Cancer	patients	often	
have	additional	risk	factors	for	bleeding,	independent	of	anticoagu‐
lation,	including	thrombocytopenia,	use	of	non‐steroidal	antiinflam‐
matory	drugs	or	antiplatelet	agents,	or	renal	dysfunction.5
Approximately	one‐third	of	all	cancer	patients	will	receive	che‐
motherapy.6	 This	poses	 further	 risks	 to	 the	 safety	and	efficacy	of	
anticoagulation,	depending	on	the	choice	of	anticoagulant.	First,	 it	
is	well	established	that	many	chemotherapeutic	agents	increase	the	
risk	of	both	arterial	and	venous	thrombosis.	Second,	chemotherapy	
regimens	 may	 independently	 increase	 the	 risk	 of	 bleeding,	 espe‐
cially	 those	 that	 induce	 thrombocytopenia.5	The	 increasing	use	of	
targeted	anticancer	therapies	such	as	tyrosine	kinase	inhibitors	and	
monoclonal	antibodies	targeting	vascular	endothelial	growth	factor	
(VEGF)	can	be	associated	with	an	increased	risk	of	bleeding	due	to	
off‐target	kinase	inhibition	resulting	in	platelet	dysfunction7,8 or the 
inhibition	of	angiogenesis	pathways.	Finally,	all	anticoagulants	that	
are	licensed	for	NVAF	have	potential	to	interact	with	some	chemo‐
therapy	and	supportive	care	drugs,	increasing	the	risk	of	bleeding	or	
stroke	depending	on	their	metabolic	pathways.
Chemotherapy	can	further	increase	the	risk	of	developing	NVAF;	
cisplatin,	melphalan,	and	cyclophosphamide	appear	to	be	associated	
with	 a	 risk	 of	 15%	 to	 30%.1	 Similarly,	monoclonal	 antibodies	 (e.g.	
trastuzumab)	and	targeted	cancer	therapies	(e.g.	ibrutinib)	are	asso‐
ciated	with	an	increased	incidence	of	NVAF	due	to	their	off‐target	
effects.9‒11	Compared	with	those	without,	cancer	patients	with	new‐
onset	NVAF	have	a	two‐fold	increased	risk	of	thromboembolism.12
Clinical	decision‐making	tools	to	inform	anticoagulation	in	NVAF	
are	well	established	in	the	general	population	and	embedded	in	clin‐
ical	practice.13‒15	While	tools	such	as	CHA2DS2‐VASC,	HAS‐BLED,	
and	HEMORR2HAGES	are	validated	to	stratify	according	to	stroke	
or	 bleeding	 risk	 in	NVAF,	 they	 do	 not	 take	 into	 consideration	 the	
additional	risks	conferred	by	the	malignant	state,	the	heterogeneity	
of	cancer,	or	the	varying	thrombotic/bleeding	risks	associated	with	
chemotherapy.	The	BleedMAP	score	 is	derived	from	retrospective	
analysis	of	2484	cases	of	oral	anticoagulant	interruptions	and	is	the	
only	bleeding	risk	tool	to	include	cancer	as	an	independent	risk	fac‐
tor	(HR,	1.8;	95%	CI,	1.0‐3.1).16	There	are	very	few	data	to	quantify	
the	risk	of	ischemic	stroke	due	to	cancer	accurately.	One	study	using	
Surveillance	Epidemiology	and	End	Results	(SEER)	Medicare	linked	
data	 of	 279	719	 patients	with	 a	 new	primary	 diagnosis	 of	 breast,	
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lung,	prostate,	colorectal,	bladder,	pancreatic,	and	gastric	cancer	ob‐
served	a	1‐year	stroke	incidence	up	to	6.3%.17	Another	study	using	
data	of	327	389	newly	diagnosed	cancer	patients	showed	the	risk	
of	stroke	differed	among	different	cancers	with	a	1‐year	cumulative	
stroke	incidence	of	3.6%	(prostate),	3.9%	(breast),	4.7%	(colorectal),	
and	8.1%	(lung).18
In	summary,	the	management	of	anticoagulation	regimens	in	can‐
cer	patients	receiving	chemotherapy	is	unclear.	There	are	no	current	
guideline	recommendations	and	wide	variation	in	clinical	practice.
1.1 | Current evidence for antithrombotic therapy 
in non‐valvular atrial fibrillation in cancer patients
There	are	limited	data	regarding	anticoagulation	for	cancer	patients	
with	NVAF	 receiving	 chemotherapy.	 Consequently,	 in	 formulating	
these	guidance	statements,	data	from	other	populations	or	clinical	
scenarios	have	been	extrapolated	and	considered	in	the	context	of:
•	 Efficacy	(stroke	prevention)
•	 Safety	(major	bleeding,	clinically	relevant	non‐major	bleeding)
•	 Drug‐drug	interactions	(chemotherapy	and	supportive	care	drugs)
•	 Patient	preference	and	quality	of	life
1.1.1 | Vitamin K antagonists
Vitamin	K	 antagonists	 (VKAs)	 such	 as	warfarin	 reduce	 the	 risk	 of	
stroke	by	two‐thirds	in	patients	with	NVAF	when	compared	to	pa‐
tients	 on	 aspirin	 or	 placebo.19	However,	 cancer	 patients	 receiving	
warfarin	 be	 it	 for	 NVAF	 or	 venous	 thromboembolism	 (VTE)	 have	
worse	 anticoagulation	 control	 and	 worse	 outcomes	 compared	
with	 cancer‐free	 controls,	 including	 a	 six‐fold	 increase	 in	 bleeding	
rates.20‒22	Furthermore,	 the	development	of	cancer	 in	patients	on	
long‐term	warfarin	is	associated	with	a	significant	reduction	in	the	
time	 in	therapeutic	range,	particularly	within	the	first	6	months	of	
cancer	diagnosis.23	Moreover,	its	use	is	further	complicated	through	
food	and	drug‐drug	interactions	by	the	following	mechanisms:
•	 Induction	or	inhibition	of	cytochrome	P450	isozymes
•	 Displacement	of	binding	from	plasma	proteins
•	 Alterations	in	vitamin	K	status
Despite	these	challenges,	warfarin	has	been	the	mainstay	of	anticoag‐
ulation	for	NVAF	for	many	years.	Warfarin	requires	frequent	monitor‐
ing	of	the	international	normalized	ratio,	which	has	been	shown	to	have	
a	negative	impact	on	quality	of	life.24
1.1.2 | Direct oral anticoagulants
Four	direct	oral	anticoagulants	(DOACs)	are	approved	and	indicated	
for	 stroke/systemic	 embolism	 prevention	 in	 patients	with	NVAF,	
although	their	approval	 for	use	varies	across	countries.	These	 in‐
clude	 the	 direct	 thrombin	 inhibitor	 dabigatran	 and	 the	 factor	 Xa	
inhibitors	 rivaroxaban,	 apixaban,	 and	 edoxaban.	 The	 advantages	
of	DOACs	 include	 predictable	 pharmacokinetics	 and	 rapid	 onset	
and	offset,	which	facilitate	the	management	of	anticoagulation	 in	
case	of	 invasive	procedure.	Several	trials	have	demonstrated	that	
DOACs	 are	 at	 least	 as	 effective	 as	warfarin	 in	 the	 prevention	of	
stroke/systemic	embolism	in	patients	with	NVAF.25‒28	A	metaanal‐
ysis	 of	 these	 trials	 showed	 that	 DOACs	 significantly	 reduced	
stroke	or	systemic	embolic	events	by	19%	compared	with	warfa‐
rin	(RR	0.81;	95%	CI	0.73‐0.91;	P	<	.0001),	which	was	mainly	due	
to	a	reduction	in	hemorrhagic	stroke	(RR	0.49;	95%	CI	0.38‐0.64;	
P	 <	 .0001).29	 The	DOACs	 also	 reduced	 all‐cause	mortality	 (0.90,	
0.85‐0.95;	P =	.0003)	and	intracranial	hemorrhage	(0.48,	0.39‐0.59;	
P <	.0001),	but	increased	gastrointestinal	bleeding	(1.25,	1.01‐1.55;	
P =	.04).
Most	 of	 these	 studies	 excluded	 cancer	 patients	 directly	 (RELY	
and	 ENGAGE	 studies)	 or	 indirectly	 (ROCKET	 AF	 and	 ARISTOLE	
studies),	by	excluding	patients	with	an	expected	survival	less	than	1	
or	2	years.	Therefore,	whether	these	results	could	be	extrapolated	
to	 cancer	 patients	 is	 unknown.	 However,	 secondary	 analyses	 of	
these	studies	in	patients	with	or	without	a	history	of	cancer	or	in	pa‐
tients	who	developed	cancer	after	enrollment	have	shed	some	light	
on	DOAC	use	 in	 the	cancer	population.	 In	 the	ROCKET	AF	study,	
the	efficacy	and	safety	of	rivaroxaban	and	warfarin	in	460	patients	
with	history	of	cancer	were	similar	to	those	in	patients	without	can‐
cer.30	In	the	ATRISTOLE	study,	the	safety	and	efficacy	advantages	of	
apixaban	over	warfarin	in	patients	without	a	history	of	cancer	were	
preserved	in	those	with	a	cancer	history.31	Similarly,	a	recent	anal‐
ysis	of	the	ENGAGE	AF‐TIMI	48	trial	 identified	1153	patients	who	
developed	 new	 or	 recurrent	 malignancy	 after	 randomization	 and	
revealed	that	edoxaban	was	as	effective	and	safe	as	warfarin	in	this	
subgroup.32A	recent	comparative	effectiveness	analysis	of	DOACs	
versus	warfarin	in	16	096	cancer	patients	with	AF	identified	in	the	
MarketScan	database	showed	that	the	risk	of	bleeding	and	ischemic	
stroke	in	patients	receiving	DOACs	was	similar	to	that	with	warfarin,	
except	for	apixaban,	which	was	associated	with	a	lower	risk	of	bleed‐
ing.	 Furthermore,	 all	DOACs	were	 shown	 to	 have	 reduced	 risk	 of	
VTE	complications	compared	with	warfarin.33	As	with	all	retrospec‐
tive	claims	in	database	analyses,	the	results	need	to	be	interpreted	
with caution.
All	 DOACs	 are	 substrates	 for	 the	 excretory	 permeability	 gly‐
coprotein	 (P‐gp)	 system,	while	 only	 apixaban	 and	 rivaroxaban	 are	
also	mainly	metabolized	 via	 hepatic	 cytochrome	 P450	 (CYP)	 3A4.	
As	 such,	 the	use	of	DOACs	 concomitantly	with	drugs	 that	 are	 in‐
hibitors	or	inducers	of	P‐gp	or	CYP3A4	might	result	in	variability	in	
the	extent	of	 anticoagulation,	 as	well	 as	potentially	 affecting	 can‐
cer	 therapies.	 This	 potential	 drug‐drug	 interaction	was	 taken	 into	
account	 in	 the	 HOKUSAI	 cancer‐VTE	 study,	 where	 patients	 with	
cancer‐associated	 VTE	 assigned	 to	 edoxaban	 received	 a	 reduced	
dose	when	 they	 also	 received	 concomitant	 treatment	with	potent	
P‐gp	 inhibitors.34	 Specific	 attention	 to	 potential	 interactions	 with	
cancer	therapy	should	be	paid	when	choosing	a	DOAC	for	stroke/
systemic	embolism	prevention	in	NVAF	patients	with	cancer.	Where	
cancer	therapies	exert	strong	induction/inhibition	of	both	P‐gp	and	
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CYP3A4,	 it	would	make	sense	to	observe	caution	with	all	DOACs,	
while	interaction	with	P‐gp	alone	should	alert	caution	to	just	apix‐
aban	and	rivaroxaban.
One	 final	 consideration	 should	 be	 the	 application	 of	 bleeding	
data	 from	 studies	 comparing	 DOACs	 with	 low‐molecular‐weight	
heparin	 (LMWH)	 for	 the	 treatment	 and	 secondary	 prophylaxis	 of	
VTE.34,35	 On	 the	 basis	 of	 major	 bleeding	 data,	 caution	 is	 advised	
when	 using	DOACs	 in	 patients	with	 “luminal	 gastrointestinal	 can‐
cers	with	an	 intact	primary	or	patients	with	active	gastrointestinal	
mucosal	abnormalities	such	as	duodenal	ulcers,	gastritis,	esophagitis	
or	colitis.”36	 Intuitively	 it	would	seem	sensible	to	observe	a	similar	
caution	with	anticoagulation	 for	NVAF,	particularly	during	chemo‐
therapy,	when	the	risk	of	bleeding	is	higher.
1.1.3 | Low‐molecular‐weight heparin
There	is	little	evidence	to	support	the	use	of	LMWH	for	long‐term	
stroke	prophylaxis	in	patients	with	NVAF	regardless	of	the	presence	
or	nonpresence	of	cancer.	Data	are	limited	to	its	use	as	a	periopera‐
tive‐bridging	agent	for	patients	on	warfarin.37	Despite	demonstrat‐
ing	 non‐inferiority	 compared	with	 placebo	with	 respect	 to	 stroke	
events,	LMWH	bridging	was	associated	with	a	three‐fold	increase	in	
bleeding	compared	with	placebo.38
It	 is	 a	 matter	 of	 debate	 as	 to	 whether	 perioperative	 bridging	
data	are	 sufficient	 to	 justify	using	LMWH	to	 “bridge”	anticoagula‐
tion	during	chemotherapy.	In	these	studies,	patients	rarely	received	
LMWH	 for	more	 than	2	weeks.38	 Since	many	 chemotherapy	 regi‐
mens	are	given	over	several	months,	it	is	difficult	to	surmise	whether	
long‐term	use	of	once‐daily	LMWH	for	this	indication	will	be	effec‐
tive	or	safe.
Owing	 to	 the	paucity	of	data	 supporting	 the	use	of	LMWH	to	
prevent	embolic	stroke	in	NVAF,	its	long‐term	use	for	other	condi‐
tions	has	also	been	reviewed.	Data	from	the	use	of	LMWH	for	treat‐
ment	 of	 cancer‐associated	 VTE	 give	 some	 indication	 of	 bleeding	
risks,	 assuming	 similar	 doses	 are	 used	 for	 stroke	 prophylaxis.	 The	
use	 of	 data	 from	 those	 studies	 also	 has	 the	 advantage	 that	many	
patients	with	metastatic	disease	who	were	receiving	chemotherapy	
were	included.	In	a	metaanalysis	of	eight	studies	comparing	LMWH	
with	warfarin,	the	major	bleeding	rate	with	LMWH	and	warfarin	was	
4.3%	and	4.1%,	respectively.39
1.2 | Clinical decision making and patient 
preferences
The	heterogeneity	of	cancer	extends	beyond	the	disease	and	 its	
stage	 and	 treatment.	 When	 making	 decisions	 about	 treatment	
regimens	 that	have	competing	attributes	 (in	 this	case	 the	 risk	of	
stroke	and	risk	of	bleeding)	clinicians	have	a	responsibility	to	con‐
sider	 these	within	 the	 context	 of	 individual	 patient	 preferences	
and	values.	These	are	likely	to	be	influenced	by	their	previous	ex‐
periences,	understanding,	and	wishes	for	the	future.	Quality	of	life	
studies	regarding	anticoagulation	and	cancer	have	predominantly	
focused	 on	 the	 treatment	 and	 secondary	 prophylaxis	 of	 VTE.	
These	have	suggested	LMWH	to	be	acceptable	within	the	context	
of	 the	cancer	course,	 in	part,	because	patients	place	most	value	
on	 anticoagulants	 that	 interfere	 least	 with	 their	 cancer	 treat‐
ment.40‒42	However,	while	 anticoagulation	 for	VTE	may	 be	 time	
limited,	 for	 NVAF	 it	 is	 usually	 indefinite.	 Arguably	 convenience	
in	 relation	 to	 quality	 of	 lifehas	 an	 even	 greater	 emphasis	 when	
choosing	an	anticoagulant	for	NVAF.	Most	patients	on	long‐term	
anticoagulation	will	prefer	oral	rather	than	parenteral	medication,	
although	they	may	well	be	willing	to	accept	parenteral	medication	
in	the	short	term	if	indicated,	for	example,	during	chemotherapy.	
Studies	also	suggest	that	patients	place	considerable	trust	 in	the	
advice	of	their	clinicians,	highlighting	the	importance	of	exploring	
what	matters	most	to	patients.
In	 keeping	with	 the	mantra	 “Primum	non	 nocere,”	 it	would	 be	
remiss	not	to	consider	whether	there	are	situations	when	the	pos‐
sible	benefit	 from	chemotherapy	may	be	 less	 than	 the	harm	 from	
more	serious	complications	associated	with	NVAF,	its	comorbidities,	
and	 complicating	 stable	 anticoagulation.	The	use	of	 adjuvant	 che‐
motherapy	is	standard	in	many	cancer	regimens	because	of	estab‐
lished	benefits	 in	 terms	of	overall	 and	progression‐free	 survival.43 
For	some	cancers,	however,	the	survival	improvements	may	only	be	
modest	and	when	balanced	against	an	unfavorable	toxicity	profile,	
the	role	of	adjuvant	treatments	has	been	controversial.44	In	such	pa‐
tients	receiving	anticoagulation	therapy	for	NVAF,	particularly	those	
with	 high	 CHA2DS2‐VASC,	 HAS‐BLED	 scores,	 the	 increased	 risk	
of	bleeding,	stroke,	and	drug‐drug	interactions	may	pose	a	greater	
threat	 to	 mortality/morbidity	 than	 the	 benefits	 afforded	 by	 the	
chemotherapy.
Finally,	even	when	the	risk/benefit	ratio	favors	the	concomitant	
use	of	anticoagulants	and	SACT,	it	is	important	to	recognize	that	the	
risk	profiles	of	bleeding	and	stroke	are	not	static	entities;	they	will	
change	over	time	according	to	alterations	in	platelet	count,	associ‐
ated	comorbidities,	and	disease	response.	As	such,	the	use	of	both	
chemotherapy	and	anticoagulation	should	be	regularly	evaluated	ac‐
cording	to	changes	in	treatment	plans	and	clinical	status.
1.3 | Clinical decision making/choice of DOAC
The	initial	phase	of	clinical	decision	making	will	center	on	(a)	whether	
anticoagulation	is	indicated	and	(b)	the	class	of	anticoagulant	to	be	
used.	On	the	basis	of	current	published	data	for	DOAC	use	across	
various	indications,	it	is	clear	that	the	four	DOACS	licensed	for	NVAF	
have	sufficient	clinical	differences	that	it	would	be	remiss	to	recom‐
mend	them	as	a	class	without	considering	circumstances	that	may	
favor	one	over	 another.	 Table	1	offers	 a	 comparative	 summary	of	
characteristics,	which	may	be	considered	when	choosing	one	agent	
over	 another.	 For	 example,	 trial	 and	 observational	 data	 suggest	
that	apixaban	may	be	safer	with	respect	 to	gastrointestinal	bleed‐
ing	risk,	while	rivaroxaban	and	edoxaban	have	the	strongest	phase	
4	 published	 data.	 Furthermore,	while	 all	 DOACS	 have	 interaction	
potential	 with	 P‐gp,	 edoxaban	 arguably	 has	 the	 most	 robust	 evi‐
dence	base	with	respect	to	dose	reduction	in	the	presence	of	P‐gp	
drugs,	since	this	was	prespecified	in	ENGAGE‐AF	and	HOKUSAI	and	
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HOKUSAI‐Cancer	 studies.	 However,	 it	 should	 be	 noted	 that	 new	
data	continue	to	emerge,	especially	with	respect	to	safety	outcomes.
1.3.1 | Guidance statements
The	guidance	statements	included	in	this	document	are	predicated	
on	the	following	premises:
•	 For	 each	of	 the	 clinical	 situations	described	herein,	 these	 guid‐
ance	statements	are	applicable	to	an	average	patient	using	stan‐
dard,	licensed	doses.	There	may	be	exceptional	circumstances	for	
which	these	guidance	statements	do	not	apply,	and	anticoagulant	
management,	 including	drug	dosing	and	 frequency,	would	be	at	
the	treating	physician's	discretion.
•	 	The	wording	“we	recommend”	reflects	a	strong	guidance	state‐
ment,	 whereby	 the	 clinician	 should	 adopt	 the	 practice	 in	 most	
cases.
•	 	The	wording	“we	suggest”	reflects	a	weak	guidance	statement,	
whereby	the	clinician	may	adopt	the	practice	in	some	cases	and	
an	alternative	practice	also	may	be	acceptable.
1.4 | Guidance statement
1.	 We	 recommend	 individualized	 anticoagulation	 regimens	 after	
shared	 decision	making	with	 patients,	 based	wherever	 possible	
on	 risk	 of	 stroke,	 bleeding,	 and	 patient	 values.
2.	 In	cancer	patients	with	NVAF	already	on	an	anticoagulant	 regi‐
men	 before	 starting	 chemotherapy,	 we	 recommend	 continuing	
the	same	anticoagulation	regimen	unless	there	are	clinically	rel‐
evant	drug‐drug	interactions.	
a	 In	cancer	patients	on	chemotherapies	with	clinically	relevant	
VKA	interactions,	we	suggest	considering	a	DOAC	if	no	addi‐
tional	drug‐drug	interactions	with	DOAC	or	close	monitoring	
of	VKA	(target	international	normalized	ratio	between	2	and	
3).
b	 In	 cancer	 patients	 on	 chemotherapies	 unable	 to	 tolerate	 an	
oral	 route	 of	 administration	 (e.g.	 nausea	 and	 vomiting),	 we	
suggest	the	use	of	parenteral	anticoagulation	with	therapeutic	
dosing	of	LMWH	with	resumption	of	oral	anticoagulation	as	
soon	as	possible.
3.	 In	cancer	patients	on	chemotherapy	with	newly	diagnosed	NVAF,	
with	the	exception	of	patients	with	luminal	gastrointestinal	can‐
cers	with	 an	 intact	 primary	or	 patients	with	 active	 gastrointes‐
tinal	 mucosal	 abnormalities	 such	 as	 duodenal	 ulcers,	 gastritis,	
esophagitis,	or	colitis,	we	suggest	the	use	of	a	DOAC	over	a	VKA	
or	LMWH	as	anticoagulant	therapy	if	no	clinically	relevant	drug‐
to‐drug	interactions	are	expected.
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TA B L E  1  Comparison	of	different	attributes	of	different	DOACs	when	considering	anticoagulation	for	NVAF	in	patients	with	cancer
DOAC
Once or 
twice a 
day
Renal 
elimination
Hepatic 
elimination
CYP3A4 
interaction
P‐gp 
substrate
Strength of RCT 
data for CAT
Strength of real 
world data for 
cancer and NVAF
Bleeding risk in 
cancer/NVAF
Apixaban b.d. 27% 73% + + + + +
Dabigatran b.d. 80% 20% − + + + ++
Edoxaban o.d. 50% 50% − + +++ ++ ++
Rivaroxaban o.d. 35% 65% + + ++ ++ ++
Abbreviations:	CAT,	cancer‐associated	thrombosis;	CYP3A4,	Cytochrome	P450	3A4;	DOACs,	direct	oral	anticoagulants;	NVAF,	non‐valvular	atrial	
fibrillation;	P‐gp,	P	glycoprotein;	RCT,	randomized	control	trial.
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